Oral Nicotine Pouch Packaging Faces a New Experimental Test
Oral nicotine pouches have moved quickly from a niche product to a visible part of the U.S. nicotine market, and the packaging has become part of the product itself. In this randomized trial protocol, investigators will examine how nicotine concentration and nicotine source claims on oral nicotine pouch packaging shape attention, perceptions, intentions, and actual product trial among young adults and adults across three user groups. The study is designed around a simple but clinically important question: do package cues encourage harm reduction among people who already use tobacco, while also making the product more attractive to young people who do not use tobacco but may be susceptible to it?
The concern is not abstract. Packaging can function as a fast, high-impact marketing tool, especially when it uses terms such as “tobacco free” or “synthetic nicotine” and displays nicotine strength prominently. Those cues may communicate reassurance to one person and novelty or strength to another. In nicotine regulation, those differences matter because a product may look like a lower-risk substitute to an established tobacco user and a low-risk starter product to a nonuser at the same time.
This protocol was developed to capture those competing effects in real time. Participants will view oral nicotine pouch package images while investigators collect psychophysiological signals, then measure perceptions, use intentions, and a behavioral outcome: whether participants choose to try a pouch when the opportunity is presented.
How the Trial Will Separate Packaging Effects From User History
The study will enroll 450 participants between 2024 and 2027, divided evenly into three groups: 150 young adults ages 18–24 who are susceptible but do not use tobacco, 150 young adults ages 18–24 who currently use tobacco, and 150 adults ages 25–65 who currently use tobacco. Recruitment began on March 4, 2024, and data collection is expected to continue through August 31, 2027, with results anticipated in January 2028. The design is a single-visit, between-subjects randomized trial at The Ohio State University Comprehensive Cancer Center in Columbus.
Each participant will be randomized into one of nine conditions in a 3 x 3 design. The first factor is nicotine concentration: none on the label, low, or high. The second factor is nicotine source claim: none, “tobacco free,” or “synthetic nicotine.” During the laboratory visit, participants will view 16 oral nicotine pouch package images in random order, with brands and flavors varying across the stimuli. While they are exposed to the images, the team will record heart rate, skin conductance, and visual attention with eye-tracking and electrocardiographic and electrodermal measures.
Those physiological measures are central to the protocol. A package that draws the eyes longer or produces more autonomic arousal may be doing more than communicating information; it may be capturing cognitive resources in a way that can precede interest, curiosity, or willingness to try. In nicotine research, these signals often serve as early markers of salience, reward expectancy, or perceived product relevance. The packaging itself becomes the stimulus, and the body’s response helps reveal how much the stimulus is penetrating.
One sentence captures the regulatory stakes: the same package feature can be read as protection, permission, or invitation.
After exposure, participants will complete self-report measures of oral nicotine pouch perceptions and intentions to use the products. They will then move into a timed behavioral task in which they are shown packages that match the condition they were assigned and the brands and flavors featured in the images. They can choose to try one of the products, and that decision serves as the behavioral endpoint for product trial. The pouches used in the task do not contain nicotine; they contain commercially available pouches with food-grade ingredients. Participants are then debriefed and compensated.
Why Nicotine Strength and Source Claims Could Pull in Different Directions
The protocol is grounded in a tension familiar to tobacco regulators and clinicians. Oral nicotine pouches do not contain tobacco leaf and they avoid combustion, so they may carry lower toxicant exposure than cigarettes. For adults who smoke, that could make them useful as a substitute or a step toward quitting. Yet lower toxicant exposure does not erase the risk that the product may normalize nicotine use, especially if marketing cues intensify appeal among people who are not already using tobacco.
Nicotine concentration labels may signal strength, satisfaction, or dependence potential. A “high” concentration label may suggest a more potent effect, while “low” or absent concentration labeling may be read as less intense and perhaps less risky. Source claims may be even more psychologically charged. “Tobacco free” can imply purity or safety, even though the product still delivers nicotine. “Synthetic nicotine” may sound modern or cleaner, potentially shifting perceived risk away from tobacco-associated harm. Those interpretations can differ sharply between current tobacco users and young adults who are susceptible but not yet using tobacco.
The investigators expect stronger effects among current tobacco users than among susceptible nonusers. That expectation reflects a plausible behavioral pattern: established users may view oral nicotine pouches through a substitution lens, while susceptible nonusers may interpret the same package as a lower-barrier way to experiment with nicotine. If the hypotheses hold, higher nicotine concentration and “tobacco free” claims will increase visual and cognitive engagement, lower perceived risk, increase intentions to use, and raise the likelihood of trial.
Two prior experimental studies point in different directions. One found that lower nicotine concentration and tobacco free claims were perceived as less harmful among adults who smoke cigarettes. Another found that packages with higher nicotine concentration were viewed as less harmful and less addictive in adults who use tobacco and those who do not. This protocol attempts to resolve that inconsistency by combining physiological, perceptual, and behavioral outcomes in a single design and by separating young susceptible nonusers from current users across age strata.
The broader public health question is straightforward even if the answer is not. If packaging cues are powerful enough to shift risk perception and product trial, regulation may need to address not just what the pouch contains, but how the pouch is presented. If the cues mainly influence existing tobacco users, the same label could support switching. If they also reach susceptible young adults, the package may become part of the recruitment machinery for a new generation of nicotine users.
The study does not yet provide results, and its protocol status leaves the actual magnitude of these effects unknown. It does, however, define a rigorous path for measuring them, from eye movement to autonomic arousal to the act of trying the product. For tobacco regulatory science, that sequence is the point: packaging may not be a passive wrapper, but a biologically and behaviorally active component of the product itself.